Silexion Therapeutics Corp. Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Dec 16, 2025 · CIK: 2022416
Sentiment: neutral
Topics: name-change, corporate-event, rebranding
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (fka Biomotion) filed an 8-K on 12/16/25, looks like a name/focus change.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 16, 2025. The filing indicates a change in the company's name and potentially its business focus, as it is now listed under "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)" with SIC code 2836. The company is incorporated in the Cayman Islands and its principal executive offices are located in Ramat-Gan, Israel.
Why It Matters
This 8-K filing signals a significant corporate event, likely a rebranding or strategic shift for Silexion Therapeutics Corp., which could impact investor perception and future business operations.
Risk Assessment
Risk Level: medium — The filing indicates a name change and a shift in industry classification, which introduces uncertainty about the company's current operations and future strategy.
Key Numbers
- 2836 — SIC Code (Indicates industry classification as BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- December 16, 2025 (date) — Date of report
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat-Gan, Israel (location) — Principal executive offices
- 2836 (sic_code) — Standard Industrial Classification
FAQ
What is the specific reason for the name change from Biomotion Sciences to Silexion Therapeutics Corp?
The filing does not explicitly state the reason for the name change, only that it occurred and the new name is Silexion Therapeutics Corp.
When did the name change from Biomotion Sciences to Silexion Therapeutics Corp officially take place?
The filing indicates the date of name change was May 6, 2024.
What is the primary business focus of Silexion Therapeutics Corp. as indicated by its SIC code?
The SIC code 2836 indicates the company's focus is on BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Where are Silexion Therapeutics Corp.'s principal executive offices located?
The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the Commission File Number for Silexion Therapeutics Corp.?
The Commission File Number is 001-42253.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-12-16 08:48:08
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2534113.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 13KB
- image00001.jpg (GRAPHIC) — 10KB
- 0001178913-25-004067.txt ( ) — 252KB
- slxn-20251216.xsd (EX-101.SCH) — 5KB
- slxn-20251216_def.xml (EX-101.DEF) — 18KB
- slxn-20251216_lab.xml (EX-101.LAB) — 27KB
- slxn-20251216_pre.xml (EX-101.PRE) — 20KB
- zk2534113_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 16, 2025, Silexion Therapeutics Corp issued a press release entitled " Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer ". A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated December 16, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: December 16, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer